Journal of Clinical Oncology
Articles in this Issue
Psychologic distress amongst adolescent and young adult cancer survivors’ and parents.
10056 Background: Increasing survival in adolescent and young adult (AYA) cancer patients has led to a growing population at risk for poor psychological o...
SOX30-mediated activation of CXCL2 as promotor of PMN-MDSC recruitment and immunosuppressive microenvironment in TNBC.
e13036 Background: Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its aggressive nature and limited treatment option...
Analysis of the relationship between the number of hematoporphyrin intravesical perfusion photodynamic therapy (PDT) combined with intravesical perfusion therapy with tumor recurrence and progression in non-muscle-invasive bladder cancer (NMIBC).
e16591 Background: To understand whether increasing the number of hematoporphyrin intravesical perfusion PDT during the recurrence-free interval (RFI) can...
Use of causal modeling to uncover cell-cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients.
e14585 Background: Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 is crucial in treating breast cancer. Despite clinical success, the mechanisms by...
Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): A phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC).
TPS4232 Background: PDAC is a devastating malignancy. High-throughput genomic technologies have yielded insights regarding the molecular underpinnings and...
Evaluation of the usefulness of an immune-related adverse events interview application.
e13555 Background: Regarding the use of immune checkpoint inhibitors (ICIs), early detection of immune-related adverse events (irAEs) is important for pre...
Does the ABO gene have prognostic value for immunotherapy efficacy?
e14656 Background: The potential linkage of ABO blood group with the immune system and cancer risk has been widely studied. However, the value of ABO sing...
Targeting PARP-1 in ER-positive endocrine-resistant breast cancer.
1083 Background: Resistance to endocrine therapy (ET) in breast cancer (BC) patients is frequently associated with acquired ESR1 gene mutations like the Y...
Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis.
e16104 Background: Gastric cancer is the fifth most common cancer and the fifth leading cause of cancer-related death worldwide. One of the primary risk f...
Assessing genetic and oncobiome profiles of patients with NMIBC: A transcriptomic analysis.
e16589 Background: Non-muscle invasive bladder cancer (NMIBC) has a high propensity for recurrences. Demographic and environmental factors can alter the n...
Estrogen receptor expression in residual breast cancer following neoadjuvant chemotherapy.
529 Background: Neoadjuvant chemotherapy (NAC) is commonly administered to patients (pts) with estrogen receptor alpha (ER) negative (immunohistochemistry...
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial.
e16344 Background: Treatment options for patients (pts) with advanced neuroendocrine carcinoma (NEC) are very limited, of which etoposide and cisplatin (E...
Distinct outcomes with the detection of endemic Burkitt lymphoma, T-cell receptor (TCR) complementarity determining region-3s (CDR3s) matching known anti-HIV TCR CDR3s.
7067 Background: The adaptive immune response is represented by diverse complementary determining region 3’s (CDR3s), which frequently represent antigen c...
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.
10004 Background: Alectinib is a next generation oral inhibitor of ALK-fusion proteins, being investigated in children and adolescents with ALK-fusion bea...
Infectious complications in relapsed/refractory multiple myeloma patients treated with bispecific antibodies: Meta-analysis.
e19536 Background: Bispecific antibodies (BsABs) have emerged as promising therapeutic modalities for relapsed/refractory multiple myeloma (RRMM), with th...
The importance of time to treatment in early onset colon cancer: A National Cancer Database analysis.
e15708 Background: The incidence of colorectal cancer is on the rise among adults under the age of 50. As a largely unscreened population, they are at ris...
Impact of telehealth utilization on adherence to endocrine therapies in privately insured breast cancer patients: A claims-based cohort study.
1648 Background: Adherence to endocrine therapies is essential for reducing recurrence and improving survival in breast cancer patients. However, nonadher...
Real-world data analysis of Anti-HER2 therapy–induced cardiotoxicity in breast cancer patients: A multi-center experience from the Middle East.
e24003 Background: HER2 inhibitors have revolutionized the treatment of HER2-positive breast cancer, significantly improving survival outcomes. However, c...
Clinical features and occurrence of other cancers in patients with chronic lymphocytic leukemia and their families with <i>POT1</i> tumor predisposition syndrome.
10585 Background: Protection of telomere 1 (POT1) tumor predisposition syndrome (POT1-TPD) is a hereditary leukemia predisposition syndrome th...
Experiences and preferences of cancer survivors across the immunotherapy journey.
1635 Background: Immuno-oncology (IO) drugs are recommended by guidelines for several tumor types and can significantly improve survival in patients with...
Pilot study of a muscadine grape extract supplement to decrease fatigue among older cancer survivors.
12057 Background: Fatigue is a prevalent symptom among older cancer survivors and is associated with declines in physical function and quality of life (QO...
Efficacy and toxicity of nivolumab and ipilimumab in rare cancer brain metastases: A multi-center basket trial analysis (NCI/SWOG S1609).
2619 Background: Outcomes of patients with brain metastases (BM) treated with single or dual checkpoint inhibitors have been previously evaluated, showing...
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).
TPS9599 Background: Melanoma is the fifth most common cancer, with ~100,000 new cases and ~8000 related deaths estimated in the US for 2024. First-line sy...
Impact of COVID-19 on the stage at diagnosis and mortality of colorectal cancer.
3621 Background: When the COVID-19 pandemic started in 2020 in the US, the Centers for Medicare and Medicaid Services (CMS) recommended delaying all non-u...
Geospatial disparities in access to clinical trials for AIDS-defining malignancies in the continental United States.
e13735 Background: Persons living with HIV (PWH) have historically faced significant disparities accessing healthcare. While AIDS-related mortality contin...